Viridian CEO gets major option and RSU grants

Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions.

Rhea-AI Filing Summary

Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions. On March 2, 2026, he was granted stock options for 559,600 shares that vest in 48 equal monthly installments after the grant date, and 111,900 restricted stock units (RSUs) that vest in four annual installments starting March 2, 2026.

On March 3, 2026, 18,357 RSUs converted into an equal number of common shares as part of a prior grant that vests annually from March 3, 2025. To cover tax obligations, 7,627 common shares were disposed of at $29.32 per share through tax withholding, leaving 33,130 common shares held directly.

Insider Trade Summary

18,357 shares exercised/converted

Exercise 5 txns

Insider Mahoney Stephen F.

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	18,357	$0.00	$0.00
Exercise	Common Stock	18,357	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	7,627	$29.32	$224K
Grant/Award	Stock Option (Right to Buy)	559,600	$0.00	$0.00
Grant/Award	Restricted Stock Units	111,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 559,600 contracts (Direct); Restricted Stock Units — 166,971 contracts (Direct); Common Stock — 33,130 shares (Direct)

Footnotes (5)

1. F1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
2. F2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
3. F3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
4. F4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
5. F5. Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Viridian Therapeutics (VRDN) report for its CEO?

Viridian Therapeutics reported that CEO Stephen F. Mahoney received new equity awards and reported related vesting events. He was granted 559,600 stock options and 111,900 RSUs, and had 18,357 RSUs convert into common stock, with 7,627 shares withheld to cover taxes at $29.32 per share.

How many stock options were granted to the Viridian (VRDN) CEO in this Form 4?

The CEO received stock options covering 559,600 shares. These options vest in 48 equal monthly installments following the March 2, 2026 grant date, conditioned on his continued service. This structure spreads potential share availability over four years rather than all at once.

What restricted stock unit (RSU) awards did the VRDN CEO report?

Stephen F. Mahoney reported a grant of 111,900 RSUs on March 2, 2026. These RSUs vest over four years, with 25% vesting on each yearly anniversary of the grant date, subject to his continued service, creating a long-term, time-based equity incentive structure.

Why were 7,627 Viridian (VRDN) shares disposed of at $29.32 in the filing?

The 7,627 common shares were disposed of to satisfy tax obligations tied to equity vesting. The Form 4 labels this as a tax-withholding disposition at $29.32 per share, meaning the shares were not an open-market sale but used to pay required taxes on vested awards.

How did RSU vesting affect the Viridian (VRDN) CEO’s common stock holdings?

On March 3, 2026, 18,357 RSUs converted into 18,357 common shares. After 7,627 shares were withheld for taxes, Mahoney’s directly held common stock position was reported as 33,130 shares, reflecting the net increase in his share ownership from the vesting event.

What are the vesting terms for the CEO’s Viridian (VRDN) equity awards?

The stock options vest in 48 equal monthly installments after March 2, 2026, requiring continued service each month. The new RSUs vest 25% on each yearly anniversary of March 2, 2026, while earlier RSUs vest 25% annually from March 3, 2025 under similar service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 06:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mahoney Stephen F.

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		18,357	A	(2)	40,757(5)	D
Common Stock	03/03/2026		F		7,627	D	$29.32	33,130(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.25	03/02/2026		A		559,600		(1)	03/02/2036	Common Stock	559,600	$0	559,600	D
Restricted Stock Units	(2)	03/02/2026		A		111,900		(3)	(3)	Common Stock	111,900	$0	111,900	D
Restricted Stock Units	(2)	03/03/2026		M			18,357	(4)	(4)	Common Stock	18,357	$0	55,071	D

Explanation of Responses:

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

5. Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

	Jennifer Tousignant, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.